Publications by authors named "Michael Fluck"

Claim this Profile
A
Avelumab plus cetuximab in patients with unresectable stage III or IV cutaneous squamous cell carcinoma: clinical activity and safety results from AliCe, a single-arm multicentre phase II DeCOG trial.
Jürgen C Becker, Anja H Gesierich, Ulrike Leiter, Lisa Zimmer, Jessica C Hassel, Michael Fluck

Br J Dermatol· October 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Phase I study of intratumoral administration of CV8102 in patients with advanced melanoma, squamous cell carcinoma of the skin, squamous cell carcinoma of the head and neck, or adenoid cystic carcinoma.
Thomas Eigentler, Ioannis Thomas, Igor Samoylenko, Michael Erdmann, Lucie Heinzerling, Michael Fluck

J Immunother Cancer· February 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
Adjuvant immunotherapy with nivolumab versus observation in completely resected Merkel cell carcinoma (ADMEC-O): disease-free survival results from a randomised, open-label, phase 2 trial.
Jürgen C Becker, Selma Ugurel, Ulrike Leiter, Friedegund Meier, Ralf Gutzmer, Michael Fluck

Lancet· September 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
Adjuvant nivolumab plus ipilimumab or nivolumab alone versus placebo in patients with resected stage IV melanoma with no evidence of disease (IMMUNED): final results of a randomised, double-blind, phase 2 trial.
Elisabeth Livingstone, Lisa Zimmer, Jessica C Hassel, Michael Fluck, Thomas K Eigentler

Lancet· October 2022

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
[
[Vogt-Koyanagi-Harada-like uveitis under immune checkpoint inhibitor treatment for metastasized malignant melanoma].
Nataša Mihailovic, Jörg Dyballa, Saskia Herz, Michael Fluck, Maged Alnawaiseh

Ophthalmologe· May 2020

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
[
[Erratum to: Vogt-Koyanagi-Harada-like uveitis under immune checkpoint inhibitor treatment for metastasized malignant melanoma].
Nataša Mihailovic, Jörg Dyballa, Saskia Herz, Michael Fluck, Maged Alnawaiseh

Ophthalmologe· May 2020

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
Adjuvant nivolumab plus ipilimumab or nivolumab monotherapy versus placebo in patients with resected stage IV melanoma with no evidence of disease (IMMUNED): a randomised, double-blind, placebo-controlled, phase 2 trial.
Lisa Zimmer, Elisabeth Livingstone, Jessica C Hassel, Michael Fluck, Thomas Eigentler

Lancet· May 2020

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
T
Tolerability of BRAF/MEK inhibitor combinations: adverse event evaluation and management.
Lucie Heinzerling, Thomas K Eigentler, Michael Fluck, Jessica C Hassel, Daniela Heller-Schenck

ESMO Open· May 2019

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
T
The efficacy of re-challenge with BRAF inhibitors after previous progression to BRAF inhibitors in melanoma: A retrospective multicenter study.
Julia K Tietze, Andrea Forschner, Carmen Loquai, Heidrun Mitzel-Rink, Lisa Zimmer, Michael Fluck

Oncotarget· September 2018

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Chemosensitivity-directed therapy compared to dacarbazine in chemo-naive advanced metastatic melanoma: a multicenter randomized phase-3 DeCOG trial.
Selma Ugurel, Carmen Loquai, Patrick Terheyden, Dirk Schadendorf, Erika Richtig, Michael Fluck

Oncotarget· September 2017

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
G
Gebrauch von Komplementärmedizin bei Patienten mit metastasierendem Melanom unter Therapie mit Ipilimumab innerhalb einer klinischen Studie.
Jutta Huebner, Peter Mohr, Jan-Christoph Simon, Michael Fluck, Carola Berking

J Dtsch Dermatol Ges· May 2016

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
U
Use of complementary medicine in metastatic melanoma patients treated with ipilimumab within a clinical trial.
Jutta Huebner, Peter Mohr, Jan-Christoph Simon, Michael Fluck, Carola Berking

J Dtsch Dermatol Ges· May 2016

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Phase II DeCOG-study of ipilimumab in pretreated and treatment-naïve patients with metastatic uveal melanoma.
Lisa Zimmer, Julia Vaubel, Peter Mohr, Axel Hauschild, Jochen Utikal, Michael Fluck

PLoS One· December 2015

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
O
Open-label, multicenter, single-arm phase II DeCOG-study of ipilimumab in pretreated patients with different subtypes of metastatic melanoma.
Lisa Zimmer, Thomas K Eigentler, Felix Kiecker, Jan Simon, Jochen Utikal, Michael Fluck

J Transl Med· November 2015

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
I
Increased level of circulating U2 small nuclear RNA fragments indicates metastasis in melanoma patients.
Jan Dominik Kuhlmann, Pauline Wimberger, Katja Wilsch, Michael Fluck, Ludwig Suter

Clin Chem Lab Med· March 2015

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
T
The price of tumor control: an analysis of rare side effects of anti-CTLA-4 therapy in metastatic melanoma from the ipilimumab network.
Caroline J Voskens, Simone M Goldinger, Carmen Loquai, Caroline Robert, Katharina C Kaehler, Michael Fluck

PLoS One· July 2013

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
Age has no significant impact on overall survival and on treatment tolerability in relapsed stage IV cutaneous malignant melanoma patients receiving Cisplatin, Gemcitabine, and Treosulfan.
Jens Atzpodien, Kerstin Terfloth, Michael Fluck, Martina Reitz

Am J Clin Oncol· February 2011

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
B
Bleomycin, vinorelbine and trofosfamide in relapsed stage IV cutaneous malignant melanoma patients.
Jens Atzpodien, Lars Morawek, Michael Fluck, Martina Reitz

Cancer Chemother Pharmacol· October 2009

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
I
Interdisciplinary management recommendations for toxicity associated with interferon-alfa therapy.
Axel Hauschild, Katharina C Kähler, Martin Schäfer, Michael Fluck

J Dtsch Dermatol Ges· October 2008

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Cisplatin, gemcitabine and treosulfan is effective in chemotherapy-pretreated relapsed stage IV uveal melanoma patients.
Jens Atzpodien, Kerstin Terfloth, Michael Fluck, Martina Reitz

Cancer Chemother Pharmacol· September 2008

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
M
Maternal gestures with 20-month-old infants in two contexts.
Maria O'Neill, Kim A Bard, Maggie Linnell, Michael Fluck

Dev Sci· July 2005

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
D
Dose-dependent treatment benefit in high-risk melanoma patients receiving adjuvant high-dose interferon alfa-2b.
Michael Fluck, Darab Kamanabrou, Andrea Lippold, Martina Reitz, Jens Atzpodien

Cancer Biother Radiopharm· June 2005

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Peptide vaccination after repeated resection of metastases can induce a prolonged relapse-free interval in melanoma patients.
Anne Letsch, Ulrich Keilholz, Michael Fluck, Dirk Nagorsen, Anne Marie Asemissen

Int J Cancer· May 2005

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
I
Individualized synthetic peptide vaccines with GM-CSF in locally advanced melanoma patients.
Jens Atzpodien, Michael Fluck, Martina Reitz

Cancer Biother Radiopharm· December 2004

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis